FIGURE 3.

Meta‐analyses of effectiveness and safety outcomes in randomised trials comparing therapeutic heparin with usual care in severely ill intensive care unit (ICU) patients with COVID‐19. Mantel‐Haenszel fixed‐effect meta‐analyses of the multiplatform trial, HESACOVID and HEP‐COVID in severely ill ICU patients. ¹⁰ , ²² , ²⁴ Squares and horizontal lines show treatment effects and their 95% confidence intervals in each trial. The area of each square is proportional to the weight the trial received in the meta‐analysis. Diamonds show estimated treatment effects and 95% confidence intervals from meta‐analyses. Odds ratios for organ support–free days alive are from ordinal logistic regression; death was assigned the worst outcome (a value of −1). Major thrombotic events were defined as the composite of myocardial infarction, pulmonary embolism, ischemic stroke, or systemic arterial embolism; any thrombotic events were defined as a major thrombotic event or deep vein thrombosis; major bleeding defined by the ISTH Scientific and Standardization Committee. The observation time for the outcomes in the trials were 28 days for the multiplatform trial (with the exception of organ support–free days, which was calculated for an observation time of 21 days), and 30 days for HEP‐COVID trial ¹⁰ , ²³